Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Treatment strategies for autoimmune hemolytic anemia.

View Full Paper
Ask AI
Bookmark
Share

Authors

TITakayuki Ikezoe

Discussion

Loading...

Member takes

Overview

Clinical guidelines endorse corticosteroids and rituximab for autoimmune hemolytic anemia, indicating new therapies may be promising.

Key Points

  • Corticosteroids effectively treat warm AIHA, while rituximab serves as a recommended second-line therapy in guidelines.
  • New drugs targeting antibody production and clearance are being developed for refractory autoimmune hemolytic anemia cases.
  • Anti-complement agents targeting C1s improve anemia in cold agglutinin disease, but do not address circulatory failure.
  • B-cell-targeted therapies are indicated for patients with severe symptoms of autoimmune hemolytic anemia.

Cite This Study

Takayuki Ikezoe (2025) studied this question.

synapsesocial.com/papers/68c1bb7854b1d3bfb60edd57https://doi.org/10.11406/rinketsu.66.565
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Management of autoimmune hemolytic anemia2025
  2. 2Autoimmune hemolytic anemia in the era of immunotherapy: from pathogenesis to therapeutic strategies2026
  3. 3[Future directions in the management of warm autoimmune hemolytic anemia].2025
  4. 4French protocol for the diagnosis and management of autoimmune hemolytic anemia in adults.2026
  5. 5Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions2025